Literature DB >> 28993129

Separating the agony from ecstasy: R(-)-3,4-methylenedioxymethamphetamine has prosocial and therapeutic-like effects without signs of neurotoxicity in mice.

Daniel W Curry1, Matthew B Young1, Andrew N Tran1, Georges E Daoud1, Leonard L Howell2.   

Abstract

S,R(+/-)-3,4-methylenedioxymethamphetamine (SR-MDMA) is an amphetamine derivative with prosocial and putative therapeutic effects. Ongoing clinical trials are investigating it as a treatment for post-traumatic stress disorder (PTSD) and other conditions. However, its potential for adverse effects such as hyperthermia and neurotoxicity may limit its clinical viability. We investigated the hypothesis that one of the two enantiomers of SR-MDMA, R-MDMA, would retain the prosocial and therapeutic effects but with fewer adverse effects. Using male Swiss Webster and C57BL/6 mice, the prosocial effects of R-MDMA were measured using a social interaction test, and the therapeutic-like effects were assessed using a Pavlovian fear conditioning and extinction paradigm relevant to PTSD. Locomotor activity and body temperature were tracked after administration, and neurotoxicity was evaluated post-mortem. R-MDMA significantly increased murine social interaction and facilitated extinction of conditioned freezing. Yet, unlike racemic MDMA, it did not increase locomotor activity, produce signs of neurotoxicity, or increase body temperature. A key pharmacological difference between R-MDMA and racemic MDMA is that R-MDMA has much lower potency as a dopamine releaser. Pretreatment with a selective dopamine D1 receptor antagonist prevented SR-MDMA-induced hyperthermia, suggesting that differential dopamine signaling may explain some of the observed differences between the treatments. Together, these results indicate that the prosocial and therapeutic effects of SR-MDMA may be separable from the stimulant, thermogenic, and potential neurotoxic effects. To what extent these findings translate to humans will require further investigation, but these data suggest that R-MDMA could be a more viable therapeutic option for the treatment of PTSD and other disorders for which SR-MDMA is currently being investigated.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Enantiomers; MDMA; Neurotoxicity; PTSD; Prosocial

Mesh:

Substances:

Year:  2017        PMID: 28993129      PMCID: PMC5714650          DOI: 10.1016/j.neuropharm.2017.10.003

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  58 in total

1.  Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine ("ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice.

Authors:  William E Fantegrossi; Tomek Godlewski; Rachel L Karabenick; Jermaine M Stephens; Thomas Ullrich; Kenner C Rice; James H Woods
Journal:  Psychopharmacology (Berl)       Date:  2003-02-01       Impact factor: 4.530

2.  Morbidity associated with MDMA (ecstasy) abuse: a survey of emergency department admissions.

Authors:  Pinchas Halpern; Jenny Moskovich; Beni Avrahami; Yedidia Bentur; Dror Soffer; Kobi Peleg
Journal:  Hum Exp Toxicol       Date:  2010-05-20       Impact factor: 2.903

3.  Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram.

Authors:  M E Liechti; C Baumann; A Gamma; F X Vollenweider
Journal:  Neuropsychopharmacology       Date:  2000-05       Impact factor: 7.853

4.  Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB.

Authors:  Una D McCann; Zsolt Szabo; Esen Seckin; Peter Rosenblatt; William B Mathews; Hayden T Ravert; Robert F Dannals; George A Ricaurte
Journal:  Neuropsychopharmacology       Date:  2005-09       Impact factor: 7.853

5.  Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA).

Authors:  Matthew B Young; Seth D Norrholm; Lara M Khoury; Tanja Jovanovic; Sheila A M Rauch; Collin M Reiff; Boadie W Dunlop; Barbara O Rothbaum; Leonard L Howell
Journal:  Psychopharmacology (Berl)       Date:  2017-07-24       Impact factor: 4.530

Review 6.  Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA.

Authors:  Michael C Mithoefer; Charles S Grob; Timothy D Brewerton
Journal:  Lancet Psychiatry       Date:  2016-04-05       Impact factor: 27.083

7.  In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain.

Authors:  C J Schmidt; J A Levin; W Lovenberg
Journal:  Biochem Pharmacol       Date:  1987-03-01       Impact factor: 5.858

8.  Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse.

Authors:  J P O'Callaghan; D B Miller
Journal:  J Pharmacol Exp Ther       Date:  1994-08       Impact factor: 4.030

9.  Cognition in novice ecstasy users with minimal exposure to other drugs: a prospective cohort study.

Authors:  Thelma Schilt; Maartje M L de Win; Maarten Koeter; Gerry Jager; Dirk J Korf; Wim van den Brink; Ben Schmand
Journal:  Arch Gen Psychiatry       Date:  2007-06

10.  Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA).

Authors:  D E Nichols; W K Brewster; M P Johnson; R Oberlender; R M Riggs
Journal:  J Med Chem       Date:  1990-02       Impact factor: 7.446

View more
  12 in total

Review 1.  Ventral Tegmental Area Dysfunction and Disruption of Dopaminergic Homeostasis: Implications for Post-traumatic Stress Disorder.

Authors:  Peiling Zhou; Meiping Deng; Jiashan Wu; Qinghui Lan; Huifang Yang; Changzheng Zhang
Journal:  Mol Neurobiol       Date:  2021-01-11       Impact factor: 5.590

Review 2.  Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.

Authors:  Lee E Dunlap; Anne M Andrews; David E Olson
Journal:  ACS Chem Neurosci       Date:  2018-07-12       Impact factor: 4.418

3.  Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.

Authors:  Danilo De Gregorio; Argel Aguilar-Valles; Katrin H Preller; Boris Dov Heifets; Meghan Hibicke; Jennifer Mitchell; Gabriella Gobbi
Journal:  J Neurosci       Date:  2020-11-30       Impact factor: 6.167

4.  Effects of a psychedelic 5-HT2A receptor agonist on anxiety-related behavior and fear processing in mice.

Authors:  Carine Bécamel; Dimitri De Bundel; Błażej D Pędzich; Sarah Rubens; Mehdi Sekssaoui; Anouk Pierre; Andries Van Schuerbeek; Philippe Marin; Joel Bockaert; Emmanuel Valjent
Journal:  Neuropsychopharmacology       Date:  2022-04-21       Impact factor: 8.294

Review 5.  (±)-MDMA and its enantiomers: potential therapeutic advantages of R(-)-MDMA.

Authors:  Elizabeth G Pitts; Daniel W Curry; Karly N Hampshire; Matthew B Young; Leonard L Howell
Journal:  Psychopharmacology (Berl)       Date:  2017-12-16       Impact factor: 4.530

6.  Stereoselective effects of the second-generation synthetic cathinone α-pyrrolidinopentiophenone (α-PVP): assessments of conditioned taste avoidance in rats.

Authors:  Katharine H Nelson; Raul López-Arnau; Briana J Hempel; Peter To; Hayley N Manke; Madeline E Crissman; Matthew M Clasen; Kenner C Rice; Anthony L Riley
Journal:  Psychopharmacology (Berl)       Date:  2018-10-17       Impact factor: 4.530

7.  Nanoparticle encapsulation increases the brain penetrance and duration of action of intranasal oxytocin.

Authors:  Aboagyewaah Oppong-Damoah; Rokon Uz Zaman; Martin J D'Souza; Kevin Sean Murnane
Journal:  Horm Behav       Date:  2018-12-30       Impact factor: 3.587

8.  Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) and R(-) MDMA on actigraphy-based daytime activity and sleep parameters in rhesus monkeys.

Authors:  Laís F Berro; Hannah Shields; Melis Odabas-Geldiay; Barbara O Rothbaum; Monica L Andersen; Leonard L Howell
Journal:  Exp Clin Psychopharmacol       Date:  2018-06-25       Impact factor: 3.157

Review 9.  MDMA to Treat PTSD in Adults.

Authors:  Dustin Latimer; Michael D Stocker; Kia Sayers; Jackson Green; Adam M Kaye; Alaa Abd-Elsayed; Elyse M Cornett; Alan D Kaye; Giustino Varrassi; Omar Viswanath; Ivan Urits
Journal:  Psychopharmacol Bull       Date:  2021-06-01

Review 10.  Neuronal and peripheral damages induced by synthetic psychoactive substances: an update of recent findings from human and animal studies.

Authors:  Giulia Costa; Maria Antonietta De Luca; Gessica Piras; Jacopo Marongiu; Liana Fattore; Nicola Simola
Journal:  Neural Regen Res       Date:  2020-05       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.